Newsfeeds - Spark Newswire

2 minute read

UroGen Pharma Highlights Results Of Co.’s Phase 2b Study Of UGN-102 In Patients With Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer Published In ‘The Journal Of Urology’

Today, 9:34 PM

Clinically Meaningful Response and Sustained Durability Underscore Potential for UGN-102 to Become a Non-Surgical Primary Therapeutic Treatment for Patients with Highly Recurrent LG IR-NMIBC 65% Complete Response

URGN

1 minute read

FDA
News

UroGen Pharma Presents Data Showcasing Novel Clinical Data At 2021 American Urological Association Annual Meeting

By Benzinga Newsdesk

Today, 9:34 PM

UroGen Pharma Ltd. (NASDAQ:URGN) today announced final data from two key trials, evaluating the safety and efficacy of investigational agent UGN-102 (mitomycin) for intravesical solution in adult patients with low-grade

URGN

11 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 9:34 PM

On Friday morning, 155 companies achieved new lows for the year.

AAU

6 minute read

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data

By Shanthi Rexaline

Today, 9:34 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19)

ABVC

12 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 9:34 PM

Thursday morning, 173 companies reached new 52-week lows.

AAMC

1 minute read

UroGen Pharma Q2 EPS $(1.17) Beats $(1.27) Estimate, Sales $13.00M Beat $10.21M Estimate

By Benzinga Newsdesk

Today, 9:34 PM

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $(1.27) by 7.87 percent. This is a 18.75 percent increase over losses of $(1.44) per share from the

URGN

6 minute read

The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings

By Shanthi Rexaline

Today, 9:34 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3)

ABSI

24 minute read

Earnings Scheduled For August 4, 2021

By Benzinga Insights

Today, 9:34 PM

Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.

ABC

6 minute read

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs

By Shanthi Rexaline

Today, 9:34 PM

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.

ABUS

1 minute read

Uncategorized

Looking Into UroGen Pharma’s Return On Capital Employed

By Benzinga Insights

Today, 9:34 PM

UroGen Pharma (NASDAQ:URGN) reported Q1 sales of $7.49 million. Earnings fell to a loss of $26.11 million, resulting in a 4.18% decrease from last quarter. In Q4, UroGen Pharma brought in $7.97 million in sales but lost $27.25 million in earnings.

URGN